LDLR and familial hyperaldosteronism: Recently, LDLR stop-gained pathogenic variants (c.2027delG, p. Gly676Alafs*33) have been discovered to be correlated with anti-lipid efficacies including statins, ezetimibe, and clinical manifestations of FH [29].